Table 2.
Treatment delivery
| Treatment | APF-C (n = 30) | TPF-C (n = 38) | ||
|---|---|---|---|---|
| % Total dose (median, range) | No. (%) receiving <100% of total dose | % Total dose (median, range) | No. (%) receiving <100% of total dose | |
| Induction chemotherapy | ||||
| nab-Paclitaxel | 100 (67–100) | 14 (47) | – | – |
| Docetaxel | – | – | 100 (67–100) | 11 (29) |
| Cetuximab | 100 (27–100) | 14 (47) | 89 (0–100) | 21 (57) |
| Cisplatin | 100 (67–100) | 2 (7) | 100 (67–100) | 8 (21) |
| Fluorouracil | 100 (80–100) | 2 (7) | 100 (58–100) | 14 (37) |
| Chemoradiotherapy | 1 | 2 | ||
| Radiation therapy | n = 29 | n = 34 | ||
| Median dose Gy (range) | 70 (14–72) | 3 (10) | 70 (70––72) | 4 (11) |
| Median elapsed days (range) | 50 (8–69) | 50 (37–64) | ||
| Concurrent chemotherapy | n = 28 | n = 34 | ||
| Cisplatin (% patients) | 27 (93) | 29 (85) | ||
| % Total dose (range) | 76 (33–100) | 17 (57) | 71 (33–100) | 27 (71) |
| Cetuximab (% patients) | 1 (4) | 5 (15) | ||
1
Denominator is 30 patients.
2
Denominator is 38 patients.